How to set cdcl3 peak in mestrenova3/17/2024 A shift in paradigm began more than 50 years ago, following the discovery that biogenic amines, notably norepinephrine (also called noradrenaline (NA)) and serotonin (5-hydroxytryptamine, 5-HT), act as neurotransmitters in the brain. BACKGROUND OF THE INVENTIONÄepression was for a long time considered an illness of the soul but it is currently viewed as a disorder of the brain. In yet another aspect, the invention relates to 5-HT 2A agonists for use as medicament in particular for use in the treatment of a depressive disorder, more particular a 5-HT 2A agonist for the use in the treatment of treatment-resistant depression. In yet another aspect, the invention relates to mixed 5-HT 2A/5-HT 2C agonists. In another aspect, the invention relates to selective 5-HT 2A agonists. In a one aspect, the invention relates to 5-HT 2A agonists. The present invention relates to agonists of the 5-HT 2A serotonin receptors. 7, 2019, the entire contents of which are incorporated herein by reference. 5, 2020, both of which claim priority to European Patent Application No.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |